A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)

Trial Profile

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs PF 6753512 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Aug 2017 Status changed from suspended to recruiting.
    • 22 May 2017 Planned number of patients changed from 108 to 133.
    • 22 May 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top